Stereotaxis wins CE mark for Synchrony system, submits to FDA

Stereotaxis (NYSE:STXS) announced today that it received CE mark for its Synchrony system while also submitting it to the FDA for 510(k) clearance.

St. Louis-based Stereotaxis designed Synchrony to digitize and modernize the interventional cath lab. It features a slim 55″ 4K ultra-high-definition display to consolidate the viewing and control of all disparate systems in the lab. This helps to deliver an enhanced procedure experience with custom layouts, streamlined workflows, an intuitive user interface and a decluttered environment.

Synchrony works to digitize video streams with full fidelity and less than a single-frame latency for clear visualization. Its architecture allows obsolescence protection for labs as new technologies roll out in the future.

Sign up for Blog Updates